OptimizeRx Corporation
OPRX
$16.94
-$0.313-1.81%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.75M | 94.37M | 92.13M | 88.18M | 83.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.75M | 94.37M | 92.13M | 88.18M | 83.20M |
| Cost of Revenue | 37.30M | 33.85M | 32.75M | 32.98M | 31.65M |
| Gross Profit | 67.45M | 60.52M | 59.38M | 55.20M | 51.55M |
| SG&A Expenses | 59.46M | 59.46M | 61.27M | 58.56M | 58.02M |
| Depreciation & Amortization | 4.36M | 4.36M | 4.33M | 4.24M | 3.61M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.11M | 97.67M | 98.34M | 95.78M | 93.29M |
| Operating Income | 3.64M | -3.30M | -6.22M | -7.60M | -10.08M |
| Income Before Tax | -9.30M | -16.11M | -19.38M | -33.33M | -26.26M |
| Income Tax Expenses | 565.00K | -704.00K | 725.00K | -9.16M | -8.34M |
| Earnings from Continuing Operations | -9.87 | -15.41 | -20.11 | -24.17 | -17.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.87M | -15.41M | -20.11M | -24.17M | -17.91M |
| EBIT | 3.64M | -3.30M | -6.22M | -7.60M | -10.08M |
| EBITDA | 7.96M | 1.02M | -1.89M | -3.57M | -6.58M |
| EPS Basic | -0.54 | -0.84 | -1.10 | -1.33 | -1.00 |
| Normalized Basic EPS | -0.06 | -0.29 | -0.41 | -0.43 | -0.46 |
| EPS Diluted | -0.54 | -0.84 | -1.10 | -1.34 | -1.01 |
| Normalized Diluted EPS | -0.06 | -0.29 | -0.41 | -0.43 | -0.46 |
| Average Basic Shares Outstanding | 73.72M | 73.47M | 73.17M | 72.53M | 70.84M |
| Average Diluted Shares Outstanding | 74.23M | 73.47M | 73.17M | 72.53M | 70.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |